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Hepatocellular carcinoma (HCC) is a leading cause of cancer-
related death worldwide, and its burden is expected to increase
further in the next years. In spite of the advances of classical ther-
apies, such as surgery, transplantation, use of radiofrequency and
transarterial embolization, the prognosis of this neoplasm has not
considerably improved over the past few years. The advent of tar-
geted therapies and the approval of the systemic treatment of
advanced HCC with the kinase inhibitor sorafenib have provided
some hope for the future. Even if the molecular mechanisms
responsible for the onset and progression of HCC are still largely
unknown, new therapeutic targets have recently come to the
spotlight. One of these targets is the tyrosine kinase receptor
for the Hepatocyte Growth Factor, encoded by the MET gene,
known to promote tumor growth and metastasis in many human
organs. In this review we will summarize the contrasting results
obtained in vitro (in HCC cell lines) and in animal experimental
models and we will also try to analyze the reasons for the oppo-
site ﬁndings, suggesting that the HGF/MET axis can have either a
promoting or a suppressive role in the development of HCC. We
will also reconsider the evidence of activation of this pathway
in human HCCs and discuss the results of the clinical trials per-
formed with MET inhibitors. The ﬁnal purpose is to better clarify
which can be the role of MET as a therapeutic target in HCC.
 2013 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.Introduction
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(A. Columbano).in the next years. HCC in men is the ﬁfth most frequently diag-
nosed cancer worldwide, and the second leading cause of can-
cer-related death, while in women it is the seventh most
commonly diagnosed cancer and the sixth cause of cancer mor-
tality [1]. The incidence of HCC varies widely, according to geo-
graphic location, and differs among racial and ethnic groups
within the same country. These differences in HCC distribution
are probably due to variations in exposure to hepatitis viruses
and environmental pathogens.
Despite an improved treatment of viral hepatitis and an
increased screening of high-risk patients in developed countries,
only around 40% of HCC patients are eligible for potentially cura-
tive treatments (resection, transplantation, or local ablation) and
20% for chemoembolization. Around 40% of patients are diag-
nosed with advanced disease [2] and thus systemic therapy is
indicated for a considerable proportion of patients. The major
problems in developing effective therapies for HCC involve the
intrinsic chemoresistance of HCC, the pharmacologic problems
due to the presence of a diseased liver and the very advanced
stage of diagnosis. Unfortunately, the efﬁcacy of traditional che-
motherapeutic agents and their ability to produce a signiﬁcant
survival beneﬁt is questionable. In light of these unsatisfactory
results, several studies have been performed to elucidate the
molecular mechanisms underlying HCC development and pro-
gression, in order to identify targets for HCC treatment [3].
Recent progresses in the elucidation of HCC molecular path-
ways have brought to the clinic the multikinase inhibitor sorafe-
nib (active against c-RAF, b-RAF, vascular endothelial growth
factor receptor, c-KIT, and platelet-derived growth factor receptor
beta), which has provided survival beneﬁt in patients with
advanced HCC and well-preserved liver function [4], and it is
now the standard of care for patients with advanced-stage HCC
[2]. However, the beneﬁts obtained from this treatment are still
disappointing and, thus, it is mandatory to ﬁnd alternative effec-
tive treatments. Unlike other solid tumors, the speciﬁc sequence
of genetic events that sustain hepatocarcinogenesis is unknown
and, in particular, no genes to which HCC cells are ‘‘addicted’’
have been identiﬁed. The concept of oncogene addiction is quite
recent and implies that continuous activation of speciﬁc onco-
genes or inactivation of tumor suppressors is required to drive
proliferation and survival of cancer cells [5]. Clinical experience
has clearly shown that targeting the genes to which tumor cells
are addicted can give signiﬁcant therapeutic results. This is the
case, for example, of Chronic Myelogenous Leukemia (CML), in
which the targeted drug Imatinib inhibits the BCR-ABL tyrosine14 vol. 60 j 442–452
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kinase to which leukemic cells are addicted, resulting in long last-
ing remissions in CML patients.
Many studies have tried to identify genes or pathways to
which HCC cells are addicted but, probably due to the heteroge-
neity of this illness, no deﬁnitive conclusion has been achieved
yet. However, some genes have gained interest as possible ther-
apeutic targets in HCC, and among them there is the receptor
for Hepatocyte Growth Factor, the tyrosine kinase (TK) encoded
by the MET gene [6]. Indeed MET plays a role in tumor onset
and progression of different tumor types and has recently
become a very interesting and studied target. Several strategies
to inhibit MET activation are under development, such as tyro-
sine kinase inhibitors and monoclonal antibodies, and some of
them are in advanced phases of clinical trials [7].
In this review we will reconsider the existing evidence for a
role of MET in sustaining HCC progression and discuss if and
how MET can be foreseen as a therapeutic target in this
pathology.The HGF/MET axis
TheMET proto-oncogene encodes the tyrosine kinase receptor for
Hepatocyte Growth Factor (HGF) [8,9]. Upon binding to HGF, MET
becomes active and drives a complex biological program, deﬁned
as ‘‘invasive growth’’, resulting from the promotion of several
biological activities, such as cell proliferation, cell invasion and
protection from apoptosis (for a review see [10]). MET-induced
invasive growth is physiologically activated during the embry-
onic development and in adulthood during tissue regeneration.
In transformed tissues, the gain of the invasive growth program
is advantageous for cancer progression and metastasis. In fact,
constitutive MET activation can contribute to several aspects of
tumor progression, since it forces neoplastic cells to disaggregate
from the tumor mass, erode basement membranes, inﬁltrate stro-
mal matrices, and eventually colonize new territories to form
metastases [10].
Many works have investigated the MET-activated signaling
pathways that are shared with many other receptor tyrosine
kinases (RTKs), including the MAP Kinase and PI-3 Kinase-AKT
pathways, STAT3, RAC1, and the NF-KB pathway (reviewed in
[11]) (Fig. 1).
MET-driven signaling results from pathways directly activated
by this receptor, but it can also be modulated by the cross-talk
between MET and different membrane receptors, acting in com-
plex interacting networks (Fig. 2). They involve the interaction
with adhesive receptors, such as CD44 [12,13] and the a6b4 inte-
grin [14], with receptors for semaphorins [15], receptor tyrosine
kinases, such as members of the Epidermal Growth Factor Recep-
tor Family (EGFR and HER2) [16–18] and the Vascular Endothelial
Growth Factor Receptor (VEGFR) [19] and, ﬁnally, with the pro-
apoptotic receptor FAS [20]. Even if in vitro data suggest that
these cross-talks are not essential for cell survival, they can allow
a better integration of the signals present in the extracellular
environment. While in physiological conditions these networks
are probably redundant, it is likely that these interacting recep-
tors cooperate in promoting tumorigenesis and/or metastasis
and in inducing resistance to targeted drugs.
Data produced by many laboratories provide compelling evi-
dence that HGF/MET signaling plays an important role in the
development and progression of tumors. Indeed, (i) cell linesJournal of Hepatology 201ectopically overexpressing MET or HGF are tumorigenic and met-
astatic in nude mice, whereas MET down-regulation decreases
their tumorigenic potential [10]; (ii)MET- or HGF-transgenic mice
develop metastatic tumors [21–24]; (iii) aberrantMET expression
(usually overexpression) has been found in many kinds of solid
tumors and correlates with poor prognosis [25]; (iv) the unequiv-
ocal evidence linking MET and human cancer comes from the
presence of germline-activating mutations in patients suffering
from hereditary papillary renal carcinomas [26]. Deregulated
MET activation in cancer can be due to different molecular alter-
ations such as overexpression, gene ampliﬁcation, autocrine acti-
vation, presence of activating point mutations or downregulation
of MET-targeting miRNAs [7]. While overexpression can make
MET activation independent from HGF stimulation, in most cases
the ligand is still required for full receptor activation [27]. This is
also true for the receptor forms containing activating mutations
that need HGF to fully activate their kinase activity.HGF/MET and liver
Hepatocyte growth factor was discovered as a mitogenic protein
for rat hepatocytes [28], and its cDNA was cloned in 1989 [29]. In
1991, the scatter factor and the tumor cytotoxic factor, ﬁbroblast-
derived cell molecules, were shown to be identical to HGF
[30,31]. In the same year, the tyrosine kinase encoded by the
MET gene was identiﬁed as the receptor for this growth factor
[8,9].
Even if HGF was originally discovered for its mitogenic and
motogenic properties, further studies revealed its ability to sup-
press apoptotic cell death. This cytoprotective action of HGF is
responsible for liver protection from tissue damage and suppres-
sion of FAS-induced massive apoptosis of hepatocytes [32,33].
Accordingly, expression of HGF is increased in response to liver
injuries, while neutralization of endogenous HGF enhances liver
damage. The increased HGF production in these conditions is
probably due to recruitment of bone marrow-derived liver sinu-
soidal endothelial cell progenitor cells [34]. The anti-apoptotic
role of HGF has been clearly proven in hepatocyte conditional
knockout Met mice, which are hypersensitive to liver injury due
to treatment with agonistic anti-Fas antibodies, show delayed
liver regeneration, and are more prone to liver ﬁbrosis [35–37].
Animal studies also showed that Hgf and Met provide essential
signals for survival and proliferation of hepatocytes during
embryogenesis, since Hgf or Met knockout mice display consider-
ably reduced liver size, due to decreased proliferation and
increased apoptosis of hepatocytes [26,38]. These observations
indicate that the HGF/MET axis is critical for liver development,
protection and regeneration.HGF/MET alterations in human HCC
On the base of the critical role of the HGF/MET axis in controlling
hepatocyte proliferation and apoptosis, many studies have been
performed to identify genetic and functional alterations of this
signaling system in human HCC (Table 1).
As previously mentioned, in human tumors MET is activated
by gene ampliﬁcation, overexpression or activating mutations.
Takeo’s and Kondo’s [39,40] search for MET ampliﬁcation in HCCs
revealed only a very low frequency (1 out of 20 and 1 out of 594 vol. 60 j 442–452 443
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Fig. 1. MET-induced signaling pathways. Hepatocyte growth factor (HGF) promotes MET dimerization and activation. The phosphorylation of two tyrosines in the
receptor tail creates binding sites for SH2-containing intracellular proteins such as Growth factor Receptor-Bound protein 2 (GRB2), Grb2-Associated Binding protein 1
(GAB1), phospholipase Cc (PLCc), Phosphoinositide 3-Kinase (PI3K), and Signal Transducer and Activator of Transcription 3 (STAT3). These pathways originate signals that
reach the nucleus and control gene transcription and DNA replication. RAC1-dependent signals inﬂuence cytoskeletal organization.
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Fig. 2. MET interplay with other membrane receptors. MET-driven signaling can be modulated by cross talk with different membrane receptors. Interaction with
adhesive receptors ampliﬁes the signaling response and controls cytoskeletal reorganization; interaction with plexins (semaphorin receptors) allows HGF-independent MET
activation of invasive growth; association with FAS regulates induction of apoptosis; interaction with tyrosine kinase receptors controls their reciprocal activation and (for
MET-VEGFR) angiogenesis.
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Table 1. Molecular alterations of HGF/MET in human HCC.
MET alteration Findings [Ref.]
Takeo et al., 2001 [39]
1/59 cases; 22/59 chromosome 7 aneuploidy Kondo et al., 2013 [40]
4-5% in 286 patients Wang et al., 2013 [41]
Point mutations 0/24 patients Guichard et al., 2012 [42]
Overexpression Northern blot analysis; overexpression in 8/18 cases with 2-10 fold increase compared 
with the surrounding liver
Boix et al., 1994 [45].
Overexpression Northern blot analysis: 6/19 cases; 16/23 with IHC. Correlation with poor to moderate 
HCC differentiation
Suzuki et al., 1994 [46]
Overexpression Competitive RT-PCR. Overexpression in some of the 11 patients. HGF undetectable Noguchi et al., 1996 [47]
Overexpression Northern blot analysis. Met overexpression in some cases and underexpression in 
others. HGF downregulation
Selden et al., [89]
Overexpression Western blot analysis. 52% of 62 patients with Met overexpression, correlating with 
increased incidence of intrahepatic metastases and shorter 5-yr OS
Ueki et al.,1997 [44]
Overexpression IHC in 86 patients. MET overexpression in 20% and downregulation in 32%. 
HGF overexpression in 33% and downregulation in 20%
Kiss et al., 1997 [48]
Overexpression IHC and qRT-PCR in 24 HCC. MET overexpression in most of the cases. 
Underexpression of HGF
Tavian et al., 2000 [49]
Overexpression qRT-PCR in 15 patients. Overexpression of MET in poorly differentiated tumors Daveau et al., 2003 [50]
Amplification
Amplification
Amplification
1/20 cases; 3.8 fold amplification
IHC, immunohistochemistry; OS, overall survival; qRT PCR, quantitative Reverse Transcription Polymerase Chain Reaction.
JOURNAL OF HEPATOLOGYHCCs, respectively); however, aneuploidy of chromosome 7
(where both MET and HGF are located) was present in 22/59
patients. A very recent work by Wang et al. [41] examined the
genomic landscape of copy number aberrations in 286 hepatocar-
cinoma patients and identiﬁed recurrently ampliﬁed regions with
a high level of copy number changes.METwas identiﬁed as one of
the ten genes in the ampliﬁcation peak located at 7q31.2, present
in 4–5% of the cases. No ampliﬁcation of HGF, located on the
same chromosome but in a different region, was found. Concern-
ing activating point mutations, Guichard and colleagues [42],
who performed the whole exome sequencing on 24 tumors, did
not identify any activating mutation in MET.
Over the past few years, expression of MET and HGF (pro-
duced by stromal components, cancer-associated ﬁbroblasts
and endothelium in the tumor mass [43,44]) has been evaluated
in many studies. In small groups of patients (18 and 19, respec-
tively) [45,46] Northern blot analysis showed an increase of
MET mRNA in 30–40% of HCCs compared to peritumoral tissue.
While Boix et al. did not ﬁnd any correlation with clinical param-
eters, Suzuki et al. observed an association between MET overex-
pression and poor-to-moderate differentiation of cancer cells and
a non-signiﬁcant increase in the proliferative activity of tumor
cells. By competitive PCR, Noguchi and collaborators [47] found
that MET expression was increased in some cases of HCC, while
HGF was expressed at levels lower than those of the peritumoral
tissue. By western blot analysis, Ueki et al. [44] found MET over-
expression in 48% of 62 HCC patients, correlating with an
increased incidence of intrahepatic metastases. Patients with
high MET HCC had a signiﬁcantly shorter 5-year survival than
patients with low MET HCC (33.5% vs. 80.3%, respectively;
p <0.05). However, they did not ﬁnd any correlation between
HGF concentration in the tumor tissue, clinic pathological factors
and patient survival. Kiss et al. [48] analyzed 86 HCCs by immu-
nohistochemistry and found MET overexpression in 20% and
downregulation in 32% of cases, while HGF was increased in
33% and decreased in 21% of tumors. Tavian et al. [49] performed
RT-PCR on 24 HCCs and found overexpression of MET and under-Journal of Hepatology 201expression of HGF compared to the corresponding peri-tumoral
tissues. HGF and MET levels did not correlate with clinical fea-
tures, but increased MET was inversely associated with patient
survival. Finally, Daveau et al. [50] performed quantitative RT-
PCR on 15 HCCs and peritumoral tissues and found low levels
of HGF in highly differentiated tumors, whereas overexpression
of MET was observed in poorly differentiated tumors and in
patients with early tumor recurrence.
As it can be seen by the overall analysis of these works, while
most of the studies agree on the decrease of HGF in HCC, it is dif-
ﬁcult to draw a deﬁnitive picture on the status and role of MET in
liver cancer. In fact, there is not only disagreement on the per-
centage of tumors showing MET overexpression, but opposite
results are often present in the literature. Which are the explana-
tions for these discrepancies? One possible reason is the use of
different techniques (Northern blot, Western blot, competitive
PCR, RT-PCR), which have different sensitivity and different
modality of quantiﬁcation. Moreover, even when the same tech-
nique is used, there is no agreement on the adopted scoring sys-
tem. Another possible reason is that many of these studies have
been performed on small groups of patients and, due to the dif-
ferent etiologies of HCC, they could have included unbalanced
types of tumors. Most importantly, none of these studies investi-
gated the activation status of MET, which is critical to identify
tumors that can beneﬁt from anti-MET drugs. As MET ampliﬁca-
tion or mutation seem to be very rare, the only criterium to select
patients for possible anti-MET therapies is overexpression, but –
at the moment – there is no standardized test to identify a level
of expression that could render tumor cells ‘‘addicted’’ to MET.
This is even more important if we think that most of the studies
found decreased HGF levels in HCC, suggesting that MET activa-
tion has to be largely ligand-independent, such as that due to
very high levels of overexpression. Alternatively, as shown by
two studies [51,52], MET could be activated by the binding with
des-gamma-carboxy prothrombin (DCP), a well-recognized
tumor marker recently exploited due to its high sensitivity
and speciﬁcity in the screening and diagnosis of hepatocellular4 vol. 60 j 442–452 445
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carcinoma. DCP is elevated in the serum of 44–81% of HCC
patients [53] and was shown to be able to bind MET, causing
its autophosphorylation and the proliferation of HCC cells [51].
Even if further studies are required to draw a ﬁnal conclusion,
it is thus possible that in many HCCs MET activation is not due
to HGF but to the autocrine/paracrine production of DCP.
A different approach to investigate the role of MET activation
in human tumors was taken by Kaposi-Novak and colleagues
[54]. Using global gene expression proﬁling of WT and Met-deﬁ-
cient primary mouse hepatocytes, the authors deﬁned a Met-
dependent gene expression signature. To assess the importance
of this signature, they applied a comparative functional genomic
approach to 242 human HCCs and liver metastases. The analysis
revealed that a subset of human HCCs and all liver metastases
shared the Met-driven expression signature, which correlated
with increased vascular invasion rate, microvessel density and
decreased mean survival time of HCC patients. Thus, they con-
cluded that Met-driven expression signature deﬁnes a subset of
human hepatocellular carcinomas with poor prognosis and
aggressive phenotype.
In vitro preclinical data of HGF/MET inhibition/overexpression
Many in vitro studies have evaluated the effect of the activation of
the HGF/MET axis in HCC cell lines. Interestingly, the ﬁrst studies
aimed at demonstrating a pro-proliferative role of HGF in liver
tumor cells, as observed in normal hepatocytes, showed a marked
inhibition of cell growth [55,56]. Growth inhibition was also
observed in HCC cells stably transduced with HGF. However, HGF
stimulation resulted in increased invasiveproperties of tumor cells
[56,57]. The biochemicalmechanisms responsible for the concom-
itant anti-proliferative and pro-invasive role of HGF in HCC cells
are not fully elucidated. Shirako et al. [58] have shown in HepG2
cells that the growth inhibitory activity of HGF requires a strong
activation of ERK and up-regulation of p16 and p21 expression,
which contributes to the suppression of Cdk2 activity.
On the other hand, different studies have shown that MET
down-regulation or inhibition interferes with both cell growth
and cell invasiveness [59–61]. The reasons for the different
behavior of HGF in normal vs. transformed hepatocytes and for
the similar effects caused by HGF stimulation and MET inhibition
in HCC remain elusive. One possibility could be the availability of
other ligands able to activate MET in the liver. Suzuki et al. [51]
identiﬁed such a molecule in des-gamma-carboxy prothrombin.
DCP contains two kringle domains similar to those of HGF,
required for HGF binding to MET. They showed that DCP binds
MET and that this interaction promotes proliferation of HCC cell
lines and induces JAK1/STAT3 activation, without affecting the
Raf/MAPK and the PI3K/AKT pathways. This study thus suggests
that the HCC cells can autocrinally activate MET signaling by pro-
ducing DCP, whose expression is a bad prognostic indicator. If
this holds true, it remains to be explained why the biological
effects of DCP/MET interaction are opposite to those elicited by
HGF/MET binding in the same cells.
As mentioned above, several studies have shown that MET can
interact with different tyrosine kinase receptors; in particular, a
functional cross-talk has been demonstrated between MET and
the different members of the EGFR family [16–18]. Indeed, Met
associates with EGFR in tumor cells, and this association results
in MET phosphorylation in the absence of HGF [16]. It can thus
be hypothesized that MET phosphorylation in HCC cells could
also be due to constitutive activation of EGFR family members,446 Journal of Hepatology 201whose alterations in liver cancers have been reported [3]. The
demonstration of a functional and biologically meaningful cross
talk between MET and EGFR in HCC cells would pave the way
to the use of combination therapies targeting both receptors,
which are already in clinical trials in other tumor types.
In vivo preclinical data of MET/HGF manipulation
The critical role of the HGF/MET axis in development was well
illustrated by the effects exerted by knock-out of either Met or
Hgf in mice. Hgf- and Met-null mutant embryos fail to complete
development and die in utero [62,63]. The mutation affects the
embryonic liver, which is reduced in size and shows extensive
loss of parenchymal cells.
Several works examined the effects of genetic inactivation or
overexpression of either Met or Hgf on hepatocarcinogenesis. The
published results, however, are discordant and the reasons for
these discrepancies are not yet clear (Table 2).
Two works examined the effect of liver-speciﬁcMet knock out
in hepatocarcinogenesis [64,65]. The loss of Met signaling in
hepatocytes increased rather than suppressed tumor initiation
by DEN (N-nitrosodiethylamine), as the animals developed signif-
icantly more and bigger tumors and with a shorter latency, com-
pared to controls. The authors suggested that this was probably
due to the loss of the physiological role of Met in maintaining
normal redox homeostasis in the liver and, thus, the lack of this
activity resulted in a tumor suppressive role of Met in this con-
text. On the contrary, a protumorigenic role was observed when
Met was hydrodynamically transfected in the liver or in Met
transgenic mice [66].
In the same manner, both stimulatory and inhibitory effects of
exogenous administration of HGF on carcinogen-treated rats
have been reported [56,67,68]. In fact, while injection of HGF to
rats initiated with DEN and promoted with N-ethyl-N-hydrox-
yethylnitrosamine signiﬁcantly increased the development of
preneoplastic foci [68], Liu et al. observed a strong inhibitory
activity of HGF in rat liver tumors induced by DEN [67]. Finally,
Ogasawara et al. found that HGF promotes proliferation of prene-
oplastic hepatocytes but does not affect the growth of liver carci-
noma cells in 30-Me-DAB-treated rats [56].
Reports obtained in HGF transgenic mice are conﬂicting as
well. A pro-tumorigenic role for HGF was clearly suggested by
Sakata et al. [21], who generated Hgf transgenic mice (under
the control of the mouse metallothionein gene promoter); they
found that in adult transgenic animals, liver weight (as a percent-
age of total body weight) was at least twice the weight of wild-
type mice and the DNA labeling index of hepatocytes was signif-
icantly increased. Moreover, this proliferative stimulus triggered
the formation of hepatocellular adenomas and/or carcinomas in
most transgenic mice older than 1.5 years. In contrast, overex-
pression of a human HGF cDNA under the control of the albumin
promoter did not induce HCC [69]. These different results can be
due to at least two reasons: (i) the level of Hgf expression
achieved in the serum through the use of the metallothionein
promoter was 2–5-fold higher compared to that obtained with
the albumin promoter; (ii) Sakata used a mouse Hgf cDNA instead
of the human HGF cDNA utilized by Shiota; it is known that the
cross interaction between human HGF and mouse Met is not ade-
quate to promote the optimal activity of the receptor.
A pro-tumorigenic role of HGF was found in transgenic mice
also by Horiguchi et al. [70], who observed accelerated DEN-
induced hepatocarcinogenesis, often accompanied by abnormal4 vol. 60 j 442–452
Table 2. In vivo manipulation of HGF/MET.
In vivo manipulation Findings [Ref.]
HGF KO Impaired development of embryonic liver Uehara et al.,, 1995 [63]
HGF injection Yaono et al., 1995 [68]
HGF infusion Strong inhibition of DEN induced liver tumors Liu et al., 1995 [67]
HGF injection Increased growth of preneoplastic hepatocytes but no effect on liver
carcinoma cell growth in 3’-Me-DAB-treated rats 
Ogasawara et al., 1998 [56]
HGF transgenic mice 
(albumin promoter)
No HCC Shiota et al., 1994 [69]
HGF transgenic mice 
(metallothionine promoter)
HCC and adenomas in mice older than 1.5 yr Sakata et al., 1996 [21]
HGF transgenic mice 
(metallothionine promoter)
Accelerated DEN-induced hepatocarcinogenesis Horiguchi et al., 2002 [70]
HGF/MYC transgenic mice HGF transgene delayed the appearance of preneoplastic lesions and 
prevented malignant conversion compared to MYC alone transgenic mice
Santoni-Rugiu et al., 1996 [71]
HGF/TGFα transgenic mice HGF transgene decreased hepatocarcinogenesis compared to TGFα alone 
transgenic mice
Shiota et al., 1994 [72]
MET KO Impaired development of embryonic liver. MET null embryonic stem cells 
do not contribute to adult liver
Schmidt et al., 1995 [62]
MET KO Accelerated DEN-induced hepatocarcinogenesis Takami et al., 2007 [64]
MET KO Accelerated DEN-induced hepatocarcinogenesis Marx-Stoelting et al., 2009 [65]
transgenic mice 
HCC development by 3 mo of age Tward et al., 2005 [66]
MET hydrodynamic 
transfection in the liver
HCC development in 74% of mice transfected with MET and active 
β-catenin
Tward et al., 2005 [66]
Liver-specific
Liver-specific
Liver-specific
DEN treated mice showed a significant increase of liver preneoplastic foci
DEN, Diethylnitrosamine; TGFa, Transforming Growth Factor a; 30-Me-DAB, 30-Methyl-4-dimethylaminoazobenzene.
JOURNAL OF HEPATOLOGYblood vessel formation. Thirty-three percent of males and 23% of
female transgenic mice developed hepatocellular carcinoma,
while none of the wild-type mice developed HCC. Since the
authors also detected enhanced Met kinase activity in most of
these tumors, they concluded that HGF promotes hepatocarcino-
genesis through the autocrine activation of the HGF/MET signal-
ing pathway, in association with stimulation of angiogenesis.
On the contrary, an inhibitory role of HGF in liver carcinogen-
esis was demonstrated in double transgenic animals, where the
Hgf transgene inhibited hepatocarcinogenesis in mice over-
expressing c-myc [71] and transforming growth factor alpha
(TGFa) [72].
Therefore, in light of these results, the issue of the pro-tumor-
igenic role of HGF and MET in the liver remains to be resolved.
MET as an anti-angiogenic target
Several experimental works showed, in vitro and in vivo, that the
HGF/MET axis promotes angiogenesis. HGF is an angiogenic fac-
tor able to activate MET in endothelial cells, in part through a
direct effect [73], in part by inducing Vascular Endothelial
Growth Factor (VEGF) production and decreasing thrombospon-
din-1 expression [74]. Moreover, very recently, it has been shown
that VEGFR and MET physically interact and that VEGF enhances
recruitment of the protein tyrosine phosphatase 1B to a MET/
VEGFR2 heterocomplex, thereby suppressing HGF-dependent
MET phosphorylation and activation [19]. Consequently, VEGF
blockade restores and increases MET activity.
Following the initial observations that anti-angiogenic mole-
cules could function as potent tumor suppressors in mice, several
therapeutic strategies have attempted to interfere with tumor
growth by suppressing neo-angiogenesis. However, it has
become clear that anti-angiogenic therapies induce tumorJournal of Hepatology 201hypoxia that, in turn, allows for selection of more aggressive
tumor cells. MET transcription is induced by the hypoxia-induc-
ible factor HIF-1a in tumor cells [75,76], and MET expression
was found to be upregulated following anti-angiogenic therapies
[77]. Thus, antiangiogenic therapies can interfere with MET acti-
vation in a dual way: (i) by promoting hypoxia-induced MET-
expression and (ii) by promoting MET activity as a consequence
of VEGF blockade.
Some studies have evaluated the effect of the simultaneous
inhibition of MET and VEGFR pathways in HCC. Treatment of
SK-HEP1 cells with foretinib (an oral multikinase inhibitor target-
ing MET, RON, AXL, TIE-2, and VEGFR2 receptors) resulted in
growth inhibition, G2/M cell cycle arrest, reduced colony forma-
tion and blockade of HGF-induced cell migration [78]. In animal
models of HCC, foretinib potently inhibited tumor growth and
inhibition of angiogenesis correlated with inactivation of VEG-
FR2/MET signaling pathways. Another study was performed on
20 HCC patients, treated with tivantinib (a small kinase MET
inhibitor) plus sorafenib [79]. Overall response rate and disease
control rate were 10% and 70%, respectively. Best response was
1 complete response (CR), 1 partial response (PR), and 12 stable
diseases (SD). Among 8 patients previously treated with VEGFR
inhibitors (6 sorafenib; 1 sunitinib; 1 sorafenib plus sunitinib),
best response was 1 CR, 1 PR, and 3 SD. This study thus suggests
that the combination of tivantinib plus sorafenib may have ther-
apeutic potential in HCC patients, including those pretreated with
VEGFR inhibitors.
The HGF/MET axis as a clinical target in HCC
Although there are no approved anti-Met agents, a number of
MET/HGF inhibitors have been or are currently under study in tri-
als in cancer patients [7]. Different molecules like monoclonal4 vol. 60 j 442–452 447
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Fig. 3. Strategies to target MET signaling. The central panel shows the physiological activation pathway of MET: pro-HGF is converted into mature HGF that binds to the
receptor and induces its dimerization and activation. Schematic MET structure: sema domain: yellow rectangle; MET-related sequence: orange rectangle; tyrosine kinase
domain (purple); (P): tyrosines of the intracellular docking site. The left side of the ﬁgure shows the therapeutic strategies utilized in preclinical studies. The upper square
illustrates molecules that act as HGF antagonists (NK4, uncleavable pro-HGF and decoy MET). Geldanamycin induces MET ubiquitination and proteasomal degradation.
Speciﬁc inhibitors (SH2 competitors and inhibitors of speciﬁc downstream molecules, such as Src, PtdIns3K, MAPK or STAT3) block critical transducers. The lower square
shows the mechanisms aimed at silencing MET or HGF expression (antisense oligonucleotides, ribozymes and RNAi). The right side illustrates MET/HGF inhibitors in clinical
trials. Anti-HGF and anti-MET antibodies prevent ligand-induced activation. Many non-selective and selective small molecules inhibit MET kinase activity. Red lines
indicate the site of action of each drug.
Reviewantibodies (mAbs) against HGF or MET and speciﬁc/non-speciﬁc
MET inhibitors are now available, but most of them are still at
early stages of clinical development (Fig. 3); the data reported
so far have shown some clinical beneﬁts in patients with various
tumor types.
Concerning HCC, three TKIs have been used in Phase II clinical
trials: tivantinib, foretinib and cabozantinib (Table 3).
Tivantinib, a staurosporine derivative showing promising
activity in a variety of phase I/II clinical trials, was initially
reported as a selective, non-ATP competitive MET inhibitor [80].
This is the drug at the most advanced stage of clinical testing in
HCC; in fact, a Phase III trial (METIV) is ongoing, on the basis of
the results obtained in a phase II, double-blind, placebo-con-
trolled clinical trial [81]. This trial assessed the efﬁcacy of tivan-
tinib in patients with advanced-stage HCC and Child-Pugh A
cirrhosis, who had progressive disease during ﬁrst-line therapy448 Journal of Hepatology 201(72 patients were treated with tivantinib and 36 were assigned
to the placebo arm). The primary end-point was time to progres-
sion; the trial also included the immunohistochemistry assess-
ment of MET expression in the tumors. Time to progression
was longer for patients in the tivantinib arm than for those in
the placebo arm (1.6 months vs. 1.4 months; p = 0.04). The results
were more positive in patients with high expression of MET,
showing a median time to progression of 2.7 months vs.
1.4 months of the placebo arm. Although these results seem
encouraging, two recent works [82,83] question the mechanism
of action of the drug, as they show that tivantinib acts on micro-
tubule dynamics independently of MET and thus it behaves more
as a cytotoxic rather than a targeted drug. In fact, the authors of
these two papers provided evidence that (i) tivantinib inhibits
the growth of both MET-dependent and independent cancer cells,
(ii) it is active on cells not expressing MET, (iii) it does not inhibit4 vol. 60 j 442–452
Table 3. Clinical trials targeting MET in HCC.
Drug Targets Phase and 
dosage
Eligibility Results Adverse effects
Cabozantinib 
[88]
VEGFR2, MET, 
RET, KIT, 
FLT4, AXL
Phase II 
100 mg/die
41 pts Child-Pugh 
Score A
2 PR and 32 SD. mPFS: 4.4 mo; 
mOS: 15.1 mo. Activity irrespective 
of sorafenib pretreatment status
Frequent grade 3-4 adverse 
effects: diarrhea, palmar-
plantar erythrodysestesia 
syndrome, thrombocytopenia
Foretinib 
[87]
MET, VEGFR2, 
TIE2, FLT4; 
RON, FLT3, 
KIT, FLT1, 
PDGRFβ
Phase I/II 
30 mg/die
39 pts Child-Pugh 
Score A; no prior 
sorafenib or TKIs 
RR: 24%
SD: 58%
mTTP: 4.2 mo
mOS: 15.7 mo
Grade 3-4 adverse 
effects in ≥5% pts : 
hypertension, ascites, 
increased ALT, abdominal 
pain, hypoalbuminemia, 
hyponatriemia
Tivantinib
[81]
MET Phase II 
360 mg twice-
daily or 
240 mg twice 
daily or
placebo
107 pts
Child-Pugh Score 
A
Tivantinib vs. placebo: TTP: 1.6 vs. 
1.4 mo
PFS 1.7 vs. 1.5 mo; OS 6.6 
(7.5 in patients treated with 240 mg) 
vs. 6.2 mo
In patients with MET-high tumors, 
TTP 2.7 vs. 1.4 mo 
PFS: 2.2 vs. 1.4 mo. 
OS: 7.2 vs. 3.8 mo 
Grade 3-4 adverse 
effects in ≥5% pts: 
neutropenia, anemia, 
fatigue, thrombocytopenia, 
leucopenia, bradycardia, 
diarrhea, vomiting, nausea, 
febrile neutropenia, 
pancytopenia, sepsis 
neutropenic sepsis,
4 deaths from severe 
neutropenia
Tivantinib + 
sorafenib
[79]
Phase I 
240 or 360 mg 
Tivantinib twice-
daily + 400 mg 
sorafenib twice 
daily
20 pts
Child-Pugh Score 
A, B
1 CR, 1 PR and 12 SD
RR: 10% DCR: 70%
mPFS: 3.5 mo
Adverse effects ≥25%: 
rash, palmar-plantar 
erythrodysestesia syndrome, 
fatigue, diarrhea, nausea, 
anorexia
INC280 Phase II Patients with HCC 
and MET pathway 
dysregulation
ongoing
Tivantinib Phase III 
240 mg twice 
daily or 
placebo
Patients with HCC 
and high MET 
expression
ongoing
SD, Stable disease; mPFS, medium Progression Free Survival; mOS, medium Overall Survival; TKIs, Tyrosine Kinase Inhibitors; mTTP, medium Time To Progression; CR,
Complete Response; PR, Partial Response; RR, Response Rate; DCR, Disease Control Rate.
JOURNAL OF HEPATOLOGYMET activation in addicted cells. Altogether these results put a
strong caveat on the real ability of tivantinib to speciﬁcally target
MET. This does not imply that the drug is ineffective, but rather
that it may act through a mechanism different from the one
hypothesized. In the past, other ‘‘targeted drugs’’ turned out to
be ‘‘cytotoxic drugs’’. A notable example is iniparib, which gave
positive results in triple-negative breast cancer in a phase II trial
[84], but later on turned out not to be a PARP (poly-(ADP-ribose)
polymerase) inhibitor but rather a cytotoxic agent [85,86]. Over-
all, the results of the study by Santoro et al. should be taken with
caution, while waiting for the results of the Phase III METIV trail,
enrolling only HCC patients with high MET expression to be trea-
ted with Tivantinib.
Foretinib is an oral multikinase inhibitor targeting MET, RON,
AXL, TIE-2, and VEGFR2. Yau et al. reported the results of a phase
I/II trial (MET111645), evaluating oral foretinib as ﬁrst line ther-
apy in advanced Asian HCC patients [87]. Thirty-nine patients
were enrolled and thirty-eight were evaluable for efﬁcacy. The
primary endpoint was safety and tolerability at the maximum
tolerated dose and the secondary endpoint included antitumor
activity (objective response rate, disease stabilization rate, time
to progression and overall survival). The overall response rate
was 24%, disease stabilization rate 79% and the median time toJournal of Hepatology 201progression was 4.2 months. The most common adverse effects
were hypertension (36%), decreased appetite (23%), and pyrexia
(21%). The most common serious adverse effects were hepatic
encephalopathy (10%) and ascites (8%).
Cabozantinib is an oral inhibitor of MET, VEGFR, and RET. A
phase II randomized discontinuation trial was performed by Vers-
lype et al. [88] on 41 patients with advanced HCC and Child-Plugh
cirrhosis. After 12 weeks, only patients with a partial response
were maintained on open-label cabozantinib, while patients with
stable disease were randomized to either cabozantinib or placebo.
The primary endpoint during the randomization phase was over-
all response rate. Median PFS from the ﬁrst day of study was
4.2 months. Two out of 36 patients evaluable for tumor assess-
ment at 12 weeks achieved a conﬁrmed PR. Onemore patient ran-
domized at week 12 achieved a PR at 18 weeks. Twenty eight out
of 36 patients (78%) with P1 post-baseline scan had tumor
regression. The overall disease control rate at week 12 was 68%.
A reduction of alpha fetoprotein (AFP) >50% in patients with ele-
vated AFP at baseline was observed in 10/26 patients (38%). Inter-
estingly, previous treatment with sorafenib did not inﬂuence PFS.
At the moment, another anti-MET drug, INC280 by Novartis, is
in Phase II clinical trial, in HCC patients with MET pathway
dysregulation.4 vol. 60 j 442–452 449
Review
Conclusions
HGF was originally discovered for its ability to promote growth of
hepatocytes and thus, from the beginning, its involvement in the
development and progression of liver tumors was considered
quite likely. However, the studies performed both in vitro – in
HCC cell lines – and in animal models gave contradictory results,
suggesting either an oncogenic or a suppressive role in liver can-
cer for the HGF/MET axis. The reasons for the observed differences
are not clear. It can be hypothesized that MET overactivation can
indeed promote signaling of HCC cells, but it is not clear how this
receptor can be activated in tumor cells, since almost all the data
show that HGF-mediated MET activation leads to inhibition of
tumor growth. Several mechanisms of HGF-independent MET
activation have been described in different conditions, but they
have not been investigated in the context of liver tumors, with
the exception of the possible role of des-gamma-carboxiprotrom-
bin as an alternative MET ligand. Concerning the studies that have
shown that the loss of HGF/MET signaling can accelerate
chemically-induced carcinogenesis, it is possible – as suggested
by Takami – that MET-mediated signaling is necessary to main-
tain normal redox homeostasis in the liver, leading to the identi-
ﬁcation of an oncosuppressive role for this gene [64].
The clinical data obtained with MET inhibitors in HCC are not
very encouraging either. A further complication to the scenario is
that the best results have been obtained with a drug whose spe-
ciﬁc activity against MET has recently been questioned [82,83].
The main problems of the performed clinical studies are the
relatively small number of patients recruited and the lack of
selection for patients displaying activation of the MET signaling
pathway. The experience obtained from the studies performed
with different targeted drugs in other tumors has taught that
they are effective almost exclusively in cells addicted to the gene
targeted by the drug. If we look, for example, at non-small cell
lung cancer, EGFR inhibitors are effective when EGFR mutations
are present, while crizotinib treatment is very active only in
patients with ALK translocation. Since these latter patients are
3% of total NSCLCs, a study with crizotinib on the whole popula-
tion of NSCLC patients would securely lead to negative results,
with the risk of leaving apart a drug that could be active on a
selected population. A similar situation can occur in the case of
HCC, where patient selection based on the activation of the
MET pathway, a crucial step in targeted therapy, has never been
done. Activation due to gene ampliﬁcation or activating muta-
tions is probably infrequent, since studies evaluating those alter-
ations in the whole genome have revealed rare anomalies in the
MET gene. The situation is more complex when overexpression is
considered. Some studies have indeed revealed different degrees
of overexpression, but the results are very heterogeneous and
cannot be compared. Moreover, no proof has been given that
the observed overexpression can lead to constitutive MET path-
way activation. These evaluations, however, open new questions
because, with the currently available IHC protocols, there are no
validated techniques to detect MET phosphorylation and HGF
expression in tumor samples.
Even if the role of HGF/MET in HCC remains elusive, there are
still reasons suggesting that MET can be considered an interesting
target in HCC. However, to reach a deﬁnitive conclusion, more
focused and wider trials, carefully investigating the status of
MET and of its signaling pathway in patients’ tumors, are manda-
tory. Careful identiﬁcation of patients likely responsive to MET450 Journal of Hepatology 201targeted drugs will also allow clinical studies evaluating the efﬁ-
cacy of combination with chemotherapeutic agents or other tar-
geted therapies (such as sorafenib or EGFR-targeted drugs).
Clinical experience has, in fact, shown that these combinations
are often more effective than the molecular drugs given alone.
If the results show that indeed MET inhibition is therapeutically
effective in HCC, a novel ﬁeld will open: the search of targeted
drugs that can be safely used in a population, such as liver cancer
patients, in which liver functionality is often poor.
Key Points
• The risk to develop HCC is constantly increasing and
the molecular mechanisms underlying its development
are still poorly understood. In spite of the advances
of classical therapies and of novel targeted therapies,
the prognosis of this neoplasm has not considerably
improved over the past few years
• MET has been proposed as one of the targets of these
therapies. A deeper understanding of the role of MET
as a therapeutic target in HCC is, however, required,
in view of the contradictory data about the role of MET
and its ligand HGF in HCC development
• In vitro data show that HGF promotes proliferation
of normal hepatocytes but inhibits growth of HCC 
cells. Several mechanisms of HGF-independent MET
activation have been described, but they have not been
investigated in depth in the context of liver tumors
• On the base of preclinical data, the issue of the pro-
tumorigenic role of HGF and MET in the liver remains
to be resolved
• More focused and wider trials, investigating the status
of MET and of its signaling pathway in patients’ tumors,
are needed to gauge the efficacy of anti-Met selective
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